Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Inventory (2017 - 2023)

Avalo Therapeutics' Inventory history spans 7 years, with the latest figure at $18000.0 for Q2 2023.

  • For Q2 2023, Inventory fell 21.74% year-over-year to $18000.0; the TTM value through Jun 2023 reached $18000.0, down 21.74%, while the annual FY2022 figure was $20000.0, 47.37% down from the prior year.
  • Inventory reached $18000.0 in Q2 2023 per AVTX's latest filing, down from $19000.0 in the prior quarter.
  • In the past five years, Inventory ranged from a high of $1.0 million in Q1 2019 to a low of $3000.0 in Q4 2020.
  • Average Inventory over 5 years is $107007.2, with a median of $20000.0 recorded in 2021.
  • Peak YoY movement for Inventory: plummeted 98.45% in 2020, then surged 1166.67% in 2021.
  • A 5-year view of Inventory shows it stood at $21334.0 in 2019, then tumbled by 85.94% to $3000.0 in 2020, then soared by 1166.67% to $38000.0 in 2021, then crashed by 47.37% to $20000.0 in 2022, then dropped by 10.0% to $18000.0 in 2023.
  • Per Business Quant, the three most recent readings for AVTX's Inventory are $18000.0 (Q2 2023), $19000.0 (Q1 2023), and $20000.0 (Q4 2022).